KIT and neoplasm: While the anti‐angiogenic capacity of Axitinib has been extensively delineated, only few reports show that the anti‐tumour activity of Axitinib is also mediated by inhibition of its target kinases VEGFR1‐3, PDGFR α/β and c‐kit expressed by the tumour cells themselves 15, 16, 17, 18, 19, 20.